secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001837607-25-000049
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma appoints new CEO, advances ABP-450 biosimilar path, reports $10.4M cash
--------------------------------------------------------------------------------

- Rob Bancroft appointed President and CEO effective April 29, 2025; also joins Board. Former CEO Marc Forth remains on Board.
- Pursuing 351(k) biosimilar pathway for ABP-450 with BOTOX as reference; plans BPD Type 2a meeting with FDA in H2 2025.
- Cash and equivalents of $10.4M at March 31, 2025; expected to fund operations through Q4 2025 and planned FDA meeting.
- NYSE American accepted compliance plan; granted until August 3, 2026 to regain continued listing standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000049/0001837607-25-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000049/aeon-20250514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-25-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer